Japan headquartered pharmaceutical firm Takeda has announced that its Board of Directors have made the decision unanimously to appoint Julie Kim, currently president of Takeda’s US Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Weber retires from the company in June 2026.
Julie will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Weber will not hold a Board seat after retiring from Takeda.
Julie Kim has been the president of the US Business Unit and US country head since 2022, and a member of the Takeda Executive Team since 2019. With three decades of experience in healthcare, Julie has held leadership positions at global, regional, country and functional levels. Her extensive background covers a range of therapeutic areas, international market access, general management, marketing and emerging market development.
A committed community leader, she participated in the Massachusetts Governor’s Economic Development Planning Council in 2023 as the lead for the Life Sciences working group to advise the administration on how the life sciences industry can continue to drive economic growth for the state.
